Background: Renal calculi, sometimes referred to as kidney stones or nephrolithiasis, are crystal concretions that primarily occur in the kidney. The pathophysiology of stones, as well as their prevention and treatment, are still largely unknown. The present study has been objectively conducted to evaluate the therapeutic safety and efficacy of oral administration of Joshānda of Parsiaosh an (Adiantumcapillus-veneris Linn.) in the management of Ḥaṣāh al-Kulya (Nephrolithiasis). Methods: The present prospective observational study was conducted at the Department of Moalajat, Regional Research Institute of Unani Medicine, Naseem Bagh, Srinagar J&K with effect from April 2021 to October 2021. A total 60 patients were equally divided into test and control group on the basis of mutual consensus between patient and clinicians. Results: The present study revealed thattest drug and control drug were equally effective in resolving the subjective parameters. However, the performance of test drug was quite impressive in improving the objective parameters like USG study of urogenital system compared to control drug with a p-value of <0.0001*. Conclusion: We concluded that the experimental drug Parsiaoshan (Adiantumcapillus-veneris Linn.) exhibits lithotriptic activity and is safe and successful in the treatment of Ḥaṣāh al-Kulya (nephrolithiasis). This study also provided evidence in favour of the unani theory that the properties of muḥallil, and mufattitsudad are responsible for the therapeutic effects of litholitic drugs.